Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
The study indicates that targeting both HSP90AB1 and PARP1 presents a promising therapeutic strategy for prostate cancer. The synergistic combination of celastrol and olaparib enhances the efficacy of treatment against prostate cancer, offering a potent approach to combat this disease.
Authors
- Houqiang Xu (ORCID: https://orcid.org/0000-0002-4696-5671)
- Mengqiu Huang
- Chen Lin (ORCID: https://orcid.org/0000-0003-3356-100X)
- Xiaoyan Ma (ORCID: https://orcid.org/0000-0003-0045-4320)
Institutions
- Guizhou University (CN)
- Zunyi Medical University (CN)
- Guiyang University (CN)
- Guizhou Institute of Technology (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s12935-024-03542-8
- Citations
- 7
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.01
Funders
- National Natural Science Foundation of China